SAN DIEGO, January 11, 2022 – Meet Antonius Schuh, Ph.D. (CEO), Andreas Klostermann, Ph.D. (CSO) and Steve Zaniboni (CFO) for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.
Site Search
Recent News
- selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients
- selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development
- Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22nd to 24th, 2022